v3.19.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Total revenue $ 104,672 $ 69,096 $ 301,962 $ 200,266
COST OF REVENUE 53,840 36,775 155,049 110,111
GROSS PROFIT 50,832 32,321 146,913 90,155
Operating expenses:        
General and administrative 33,054 21,055 94,773 59,106
Research and development 2,611 446 6,407 2,475
Sales and marketing 11,508 6,900 35,048 21,355
Total operating expenses 47,173 28,401 136,228 82,936
INCOME FROM OPERATIONS 3,659 3,920 10,685 7,219
Interest expense, net 203 1,873 3,333 4,766
Other (income) expense (35) (30) 5,124 31
Loss on extinguishment of debt 0 0 1,018 0
Income before taxes 3,491 2,077 1,210 2,422
Income tax expense (benefit) 1,348 54 (500) 135
NET INCOME 2,143 2,023 1,710 2,287
Deemed dividends on preferred stock and amortization of beneficial conversion feature 0 0 0 5,627
Gain on redemption of preferred stock 0 0 0 (9,075)
NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS $ 2,143 $ 2,023 $ 1,710 $ 5,735
INCOME PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS        
Basic (in dollars per share) $ 0.02 $ 0.02 $ 0.02 $ 0.07
Diluted (in dollars per share) $ 0.02 $ 0.02 $ 0.02 $ 0.06
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING        
Basic (in shares) 103,899 87,253 99,149 87,381
Diluted (in shares) 107,880 90,899 102,766 89,925
Clinical Services        
Total revenue $ 92,565 $ 59,449 $ 267,757 $ 175,960
GROSS PROFIT 45,039 27,940 131,200 81,374
Pharma Services        
Total revenue 12,107 9,647 34,205 24,306
GROSS PROFIT $ 5,793 $ 4,381 $ 15,713 $ 8,781

Source